CL2017002701A1 - Composiciones y métodos para la vigilancia activa del cáncer de próstata. - Google Patents

Composiciones y métodos para la vigilancia activa del cáncer de próstata.

Info

Publication number
CL2017002701A1
CL2017002701A1 CL2017002701A CL2017002701A CL2017002701A1 CL 2017002701 A1 CL2017002701 A1 CL 2017002701A1 CL 2017002701 A CL2017002701 A CL 2017002701A CL 2017002701 A CL2017002701 A CL 2017002701A CL 2017002701 A1 CL2017002701 A1 CL 2017002701A1
Authority
CL
Chile
Prior art keywords
prostate cancer
methods
compositions
active surveillance
surveillance
Prior art date
Application number
CL2017002701A
Other languages
English (en)
Inventor
Andrew J Vickers
Hans Lilja
Yan Dong
Daniel Sjoberg
Peter T Scardino
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of CL2017002701A1 publication Critical patent/CL2017002701A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Data Mining & Analysis (AREA)
  • Analytical Chemistry (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Databases & Information Systems (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Algebra (AREA)
  • Computational Mathematics (AREA)
  • Mathematical Physics (AREA)
  • Software Systems (AREA)
  • Computing Systems (AREA)
  • Pure & Applied Mathematics (AREA)

Abstract

<p>ASPECTOS DE LA DIVULGACIÓN SE REFIEREN A MÉTODOS Y SISTEMAS MEJORADOS PARA LA VIGILANCIA ACTIVA DE UN SUJETO QUE TIENE CÁNCER DE PRÓSTATA NO AGRESIVO.</p>
CL2017002701A 2015-04-29 2017-10-25 Composiciones y métodos para la vigilancia activa del cáncer de próstata. CL2017002701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154616P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
CL2017002701A1 true CL2017002701A1 (es) 2018-07-06

Family

ID=57198800

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002701A CL2017002701A1 (es) 2015-04-29 2017-10-25 Composiciones y métodos para la vigilancia activa del cáncer de próstata.

Country Status (20)

Country Link
US (2) US20160320394A1 (es)
EP (2) EP3247387A4 (es)
JP (1) JP6873916B2 (es)
KR (1) KR102527446B1 (es)
CN (1) CN107530412A (es)
AU (1) AU2016254127B2 (es)
CA (1) CA2982262A1 (es)
CL (1) CL2017002701A1 (es)
CO (1) CO2017010808A2 (es)
DE (1) DE202016008673U1 (es)
EA (1) EA039028B1 (es)
HK (2) HK1247824A1 (es)
IL (1) IL254833B (es)
MX (1) MX2017013881A (es)
MY (1) MY197117A (es)
PE (1) PE20180930A1 (es)
SG (1) SG11201708289TA (es)
TW (1) TWI766836B (es)
UA (1) UA125745C2 (es)
WO (1) WO2016176529A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087999A1 (en) 2009-02-02 2010-08-05 Claros Diagnostics, Inc. Structures for controlling light interaction with microfluidic devices
CN108108590A (zh) 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
MX392384B (es) 2014-03-28 2025-03-24 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
AU2016365824B2 (en) 2015-12-11 2022-07-21 Opko Diagnostics, Llc Fluidic systems involving incubation samples and/or reagents
WO2017116979A1 (en) 2015-12-29 2017-07-06 Opko Diagnostics, Llc Fluid collection device and related methods
WO2019221930A1 (en) * 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
FI20002127A0 (fi) * 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
CA3016967C (en) 2010-04-16 2021-08-31 Opko Diagnostics, Llc Systems and devices for analysis of samples
CN108108590A (zh) * 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
CA2871877A1 (en) 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
DK2922967T3 (en) * 2012-11-20 2018-04-16 Phadia Ab PROCEDURE FOR VIEWING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATANCES
CA2891394C (en) * 2012-11-20 2023-03-14 Phadia Ab Prognostic method for individuals with prostate cancer

Also Published As

Publication number Publication date
IL254833B (en) 2021-12-01
JP6873916B2 (ja) 2021-05-19
EP3287786A2 (en) 2018-02-28
EP3247387A4 (en) 2018-09-12
CA2982262A1 (en) 2016-11-03
TW201705028A (zh) 2017-02-01
EA039028B1 (ru) 2021-11-24
EP3287786A3 (en) 2018-03-21
JP2018518661A (ja) 2018-07-12
CO2017010808A2 (es) 2018-04-19
SG11201708289TA (en) 2017-11-29
EA201792372A1 (ru) 2018-03-30
AU2016254127B2 (en) 2022-05-26
PE20180930A1 (es) 2018-06-08
AU2016254127A1 (en) 2017-10-26
MY197117A (en) 2023-05-26
TWI766836B (zh) 2022-06-11
BR112017022391A2 (pt) 2018-07-10
WO2016176529A1 (en) 2016-11-03
IL254833A0 (en) 2017-12-31
DE202016008673U1 (de) 2019-01-22
KR20180018514A (ko) 2018-02-21
HK1247559A1 (zh) 2018-09-28
KR102527446B1 (ko) 2023-05-02
US20220399121A1 (en) 2022-12-15
UA125745C2 (uk) 2022-06-01
EP3247387A1 (en) 2017-11-29
MX2017013881A (es) 2018-03-12
US20160320394A1 (en) 2016-11-03
CN107530412A (zh) 2018-01-02
HK1247824A1 (zh) 2018-10-05

Similar Documents

Publication Publication Date Title
PH12020551397A1 (en) Cot modulators and methods of use thereof
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CO2017010808A2 (es) Sistemas y métodos para la vigilancia activa del cancer de próstata
MY184870A (en) Immunomodulators
MX370807B (es) Anticuerpos que se unen a axl.
PH12016501763B1 (en) Multispecific antibodies
CL2017001393S1 (es) Automovil
CL2017001185S1 (es) Automovil
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
PH12018500950B1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX2016008771A (es) Determinantes de respuesta del cancer a la inmunoterapia.
MX2021010460A (es) Metodo de tratamiento con tradipitant.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
AU363883S (en) Tracking device
MX383748B (es) Procesos para la preparación de un compuesto de diariltiohidantoína.
GB2569488A (en) PD-1 specific aptamers
MY187959A (en) Reactor
CL2017002653A1 (es) Procedimiento y reactor para fijar arsénico.
EA201691203A1 (ru) Твёрдые формы тенофовира
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima
ITUA20161552A1 (it) Riflettore modulante per fondo pozzo
MX2017001929A (es) Activacion del factor x.